论文部分内容阅读
近年来,罕见病及其用药等相关问题逐渐引起社会公众和生物医药企业的关注。孤儿药具生产成本高、目标市场小、价格昂贵等特点,能否将其纳入到医疗保险体系中,体现出社会福利制度的公平性值得探讨。基于药物可及性可体现医疗保险制度的社会福利公平性特点,本文对传统疑难杂症药物纳入到孤儿药定义的相关问题进行了分析;具有中国特色的孤儿药定义在激励企业创新行为、研发活动体现临床价值、有效补充医疗制度和中医药产业国际化进程中等方面具有积极推动作用。
In recent years, the related problems such as rare diseases and their medication gradually aroused the public’s attention and the biomedical enterprises. Orphan drug production costs are high, the target market is small, expensive and other characteristics, whether it can be incorporated into the medical insurance system, reflecting the fairness of the social welfare system worth exploring. Based on the fact that drug accessibility can reflect the fairness of social welfare in the medical insurance system, this article analyzes the related problems of traditional inclusion drug into the definition of orphan drug. The definition of orphan drug with Chinese characteristics in encouraging enterprise innovation behavior, R & D Activities reflect the clinical value, effective replenishment of the medical system and the process of internationalization of Chinese medicine industry has a positive role in promoting.